Cancer drug toxicity: Moving from patient to survivor

Megan Slocum, Sophie F. Garcia, June M. McKoy*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Millions of individuals worldwide are living with cancer and have remained disease-free for more than 5 years. These individuals are considered to be cancer survivors. The advent of new targeted therapies and personalized treatment modalities have contributed to this increased survivorship. Additionally, earlier diagnosis and detection of cancer, greater access to preventive screenings, and greater focus on cancer pharmaceutical safety have all been contributed to increasing longevity. Of note, all cancer types have benefited in the survivorship arena. The advent of expansive survivorship care planning mandated by national governmental agencies and the emergence of newer classes of drug therapies for cancer are expected to buttress and support cancer survivorship in the coming decades.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherSpringer International Publishing
Pages107-118
Number of pages12
DOIs
StatePublished - Jan 1 2019

Publication series

NameCancer Treatment and Research
Volume171
ISSN (Print)0927-3042

    Fingerprint

Keywords

  • Cancer
  • Drug policy
  • Pharmaceutical safety
  • Survivorship

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Slocum, M., Garcia, S. F., & McKoy, J. M. (2019). Cancer drug toxicity: Moving from patient to survivor. In Cancer Treatment and Research (pp. 107-118). (Cancer Treatment and Research; Vol. 171). Springer International Publishing. https://doi.org/10.1007/978-3-319-43896-2_8